Global BCG and Tuberculosis Vaccine Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global BCG and Tuberculosis Vaccine Market Research Report 2024
Tuberculosis Vaccine is a vaccine primarily used against tuberculosis. Tuberculosis is a serious infection, which affects the lungs and sometimes other parts of the body, such as the bones, joints and kidneys. The bacille Calmette-Guérin (BCG) vaccine has existed for 80 years and is one of the most widely used of all current vaccines, reading >80% of neonates and infants in countries where it is part of the national childhood immunization programme.
According to Mr Accuracy reports new survey, global BCG and Tuberculosis Vaccine market is projected to reach US$ 93 million in 2029, increasing from US$ 76 million in 2022, with the CAGR of 3.0% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole BCG and Tuberculosis Vaccine market research.
The tuberculosis (TB) vaccination market is driven by the global efforts to combat TB and the increasing burden of the disease in high-risk populations. TB is a highly contagious bacterial infection that poses a significant public health challenge worldwide. Vaccination against TB, primarily through the Bacille Calmette-Guérin (BCG) vaccine, is essential in reducing TB incidence and severity, especially in endemic regions. The rise in TB cases and drug-resistant strains contribute to market growth as governments and healthcare organizations focus on prevention strategies. Moreover, advancements in vaccine research and development, including novel TB vaccines under investigation, have the potential to further improve TB control efforts. However, the market also faces challenges, including the variable efficacy of the BCG vaccine against different forms of TB and the need for improved vaccine coverage in high-burden areas. Additionally, addressing vaccine supply and distribution challenges and ensuring equitable access to TB vaccination can pose obstacles for comprehensive disease control. To succeed, companies must focus on research and development to offer innovative TB vaccine candidates, collaborate with global health initiatives to promote vaccination campaigns, and address the challenges to meet the increasing demand for effective TB prevention solutions.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global BCG and Tuberculosis Vaccine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Merck
Japan BCG Lab
Serum Institute of India
AJ Vaccines
BioFarma
GreenSignal Bio Pharma
China National Biotec
Biomed Lublin
Taj Pharmaceuticals
Ataulpho de Paiva
IVAC-Institute of Vaccines and Medical Biologicals
Queen Saovabha Mem. Inst
Microgen
Segment by Type
Immune Vaccine
Therapy Vaccine
Self-Procurement
UNICEF
Others
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The BCG and Tuberculosis Vaccine report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports new survey, global BCG and Tuberculosis Vaccine market is projected to reach US$ 93 million in 2029, increasing from US$ 76 million in 2022, with the CAGR of 3.0% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole BCG and Tuberculosis Vaccine market research.
The tuberculosis (TB) vaccination market is driven by the global efforts to combat TB and the increasing burden of the disease in high-risk populations. TB is a highly contagious bacterial infection that poses a significant public health challenge worldwide. Vaccination against TB, primarily through the Bacille Calmette-Guérin (BCG) vaccine, is essential in reducing TB incidence and severity, especially in endemic regions. The rise in TB cases and drug-resistant strains contribute to market growth as governments and healthcare organizations focus on prevention strategies. Moreover, advancements in vaccine research and development, including novel TB vaccines under investigation, have the potential to further improve TB control efforts. However, the market also faces challenges, including the variable efficacy of the BCG vaccine against different forms of TB and the need for improved vaccine coverage in high-burden areas. Additionally, addressing vaccine supply and distribution challenges and ensuring equitable access to TB vaccination can pose obstacles for comprehensive disease control. To succeed, companies must focus on research and development to offer innovative TB vaccine candidates, collaborate with global health initiatives to promote vaccination campaigns, and address the challenges to meet the increasing demand for effective TB prevention solutions.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global BCG and Tuberculosis Vaccine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Merck
Japan BCG Lab
Serum Institute of India
AJ Vaccines
BioFarma
GreenSignal Bio Pharma
China National Biotec
Biomed Lublin
Taj Pharmaceuticals
Ataulpho de Paiva
IVAC-Institute of Vaccines and Medical Biologicals
Queen Saovabha Mem. Inst
Microgen
Segment by Type
Immune Vaccine
Therapy Vaccine
Segment by Application
Self-Procurement
UNICEF
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The BCG and Tuberculosis Vaccine report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices